Mammary Cell News Volume 6.02 | Jan 23 2014

Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response
Researchers characterized estrogen receptor (ER) function and endocrine response in invasive lobular carcinoma models. MM134 cells were de novo tamoxifen resistant, and were induced to grow by 4-hydroxytamoxifen, as well as other anti-estrogens, as partial agonists. Growth was accompanied by agonist activity of tamoxifen on ER-mediated gene expression. [Cancer Res] Abstract

Long Non-Coding RNA UCA1 Promotes Breast Tumor Growth by Suppression of p27 (Kip1)
Scientists demonstrated that heterogeneous nuclear ribonucleoprotein I can also form a functional ribonucleoprotein complex with long non-coding RNAs urothelial carcinoma-associated 1 (UCA1) and increase the UCA1 stability. UCA1 has an oncogenic role in breast cancer both in vitro and in vivo. [Cell Death Dis]
Full Article

Integrin a3ß1 Controls mRNA Splicing that Determines Cyclooxygenase-2 (Cox-2) mRNA Stability in Breast Cancer Cells
Researchers used RNAi to suppress a3ß1 in human MDA-MB-231 breast cancer cells, then utilized exon microarrays to compare global gene expression between control and a3ß1-deficient cells. This analysis identified numerous mRNAs, including Cox-2, that showed altered expression and/or alternate exon usage in a3ß1-deficient cells. [J Cell Sci] Abstract

LAMP3 Is Involved in Tamoxifen Resistance in Breast Cancer Cells through the Modulation of Autophagy
The significance of lysosome-associated membrane protein 3 (LAMP3) for tamoxifen resistance in breast cancer was examined. Researchers showed that tamoxifen treatment of MCF7 cells induced LAMP3 mRNA expression. [Endocr Relat Cancer] Abstract

Antitumor Activity of the Recombination Polypeptide GST-NT21MP Is Mediated by Inhibition of CXCR4 Pathway in Breast Cancer
Researchers used multiple methods such as MTT assay, FACS, invasion assay, RT-PCR and western blot to explore the efficacy and mechanism by which GST-NT21MP inhibits cell growth, migration and invasion of breast cancer in vitro and in vivo. [Brit J Cancer] Abstract

Role of SNTA1 in Rac1 Activation, Modulation of ROS Generation, and Migratory Potential of Human Breast Cancer Cells
Scientists showed that a novel complex, involving alpha-1-syntrophin (SNTA1), P66shc, and Grb2 proteins, is involved in Rac1 activation. Various Rac1 activation assays and functional assays, such as migration assays, in vitro wound healing assays, cell proliferation assays, and reactive oxygen species (ROS) generation assays, were performed. [Br J Cancer] Abstract

Prolactin/Stat5 and Androgen R1881 Co-Activate Carboxypeptidase-D Gene in Breast Cancer Cells
Scientists showed that synthetic androgen R1881 and prolactin elevated carboxypeptidase-D mRNA/protein levels in human MCF-7 and T47D breast cancer cells in a time-/dose-dependent manner. [Mol Endocrinol] Abstract

SKP2 Overexpression Is Associated with Increased Serine 10 Phosphorylation of p27 (pSer10p27) in Triple-Negative Breast Cancer
Use of the triple-negative TMX2-28 breast cancer cell line to address the role of S-phase kinase-associated protein 2 (SKP2) in cell cycle progression confirmed that SKP2 contributes to a more rapid cell cycle progression and may regulates pSer10p27 levels. [J Cell Physiol] Abstract

Estrogen and Pure Antiestrogen Fulvestrant (ICI 182 780) Augment Cell-Matrigel Adhesion of MCF-7 Breast Cancer Cells through a Novel G Protein Coupled Estrogen Receptor (GPR30)-to-Calpain Signaling Axis
Researchers demonstrated that both 17-beta-estradiol and ICI enhance cell adhesion to matrigel in MCF-7 breast cancer cells, with increased autolysis of calpain 1 and proteolysis of focal adhesion kinase, indicating calpain activation. [Toxicol Appl Pharmacol] Abstract

CLINICAL RESEARCH

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Researchers report a retrospective exploratory analysis of the association of the research-based prediction analysis of microarray 50 (PAM50) subtype predictor with pathologic complete response and event-free survival in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. [Clin Cancer Res] Abstract | Press Release

Breast Cancer in Young Women after Treatment for Hodgkin’s Disease during Childhood or Adolescence: An Observational Study with Up to 33-Year Follow-Up
Data on the occurrence of secondary breast cancer were collected from 590 women who were treated in five consecutive pediatric Hodgkin’s disease (HD) treatment studies in the years 1978-1995 and then re-evaluated in a late follow-up study after a median interval of 17.8 years. Women who were treated for HD in childhood or adolescence have an increased risk of developing breast cancer as young adults. [Dtsch Arztebl Int]
Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Biotech Veteran Joe Panetta Appointed to Stem Cell Agency Board
Joe Panetta, the President and CEO of Biocom has been appointed by Governor Jerry Brown to the governing Board of the state’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine] Press Release

The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids
The HUB Foundation for Organoid Technology announced that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation. [STEMCELL Technologies Inc.] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

PhD Scholarship – Chromosome Instability in Breast Cancer (The University of Queensland)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Associate – Breast Cancer Development (University of Pittsburgh Cancer Institute)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.